GIP/GLP-1 dual drug linked to fewer deaths in real-world liver disease study

(MedPage Today) – Phoenix – The use of tirzepatide (Mounjaro, Zepbound) was associated with a significant reduction in the risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) in high-risk patients with…